Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CFLAR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CFLAR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CFLAR_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CFLAR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CFLAR_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CFLAR_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CFLAR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005254828 | Skin | cSCC | regulation of endopeptidase activity | 165/4864 | 432/18723 | 1.18e-08 | 3.63e-07 | 165 |
GO:000724925 | Skin | cSCC | I-kappaB kinase/NF-kappaB signaling | 116/4864 | 281/18723 | 1.33e-08 | 4.08e-07 | 116 |
GO:004854529 | Skin | cSCC | response to steroid hormone | 135/4864 | 339/18723 | 1.34e-08 | 4.09e-07 | 135 |
GO:004312225 | Skin | cSCC | regulation of I-kappaB kinase/NF-kappaB signaling | 105/4864 | 249/18723 | 1.70e-08 | 5.09e-07 | 105 |
GO:000188925 | Skin | cSCC | liver development | 69/4864 | 147/18723 | 3.33e-08 | 8.87e-07 | 69 |
GO:006100825 | Skin | cSCC | hepaticobiliary system development | 70/4864 | 150/18723 | 3.56e-08 | 9.33e-07 | 70 |
GO:001095227 | Skin | cSCC | positive regulation of peptidase activity | 85/4864 | 197/18723 | 1.14e-07 | 2.69e-06 | 85 |
GO:004328128 | Skin | cSCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 89/4864 | 209/18723 | 1.20e-07 | 2.79e-06 | 89 |
GO:200011628 | Skin | cSCC | regulation of cysteine-type endopeptidase activity | 97/4864 | 235/18723 | 2.01e-07 | 4.34e-06 | 97 |
GO:007048226 | Skin | cSCC | response to oxygen levels | 133/4864 | 347/18723 | 2.39e-07 | 5.07e-06 | 133 |
GO:200123628 | Skin | cSCC | regulation of extrinsic apoptotic signaling pathway | 68/4864 | 151/18723 | 3.01e-07 | 6.12e-06 | 68 |
GO:009719128 | Skin | cSCC | extrinsic apoptotic signaling pathway | 91/4864 | 219/18723 | 3.31e-07 | 6.63e-06 | 91 |
GO:0071383111 | Skin | cSCC | cellular response to steroid hormone stimulus | 84/4864 | 204/18723 | 1.44e-06 | 2.48e-05 | 84 |
GO:004343426 | Skin | cSCC | response to peptide hormone | 150/4864 | 414/18723 | 2.11e-06 | 3.43e-05 | 150 |
GO:004206029 | Skin | cSCC | wound healing | 152/4864 | 422/18723 | 2.66e-06 | 4.26e-05 | 152 |
GO:000166626 | Skin | cSCC | response to hypoxia | 116/4864 | 307/18723 | 3.09e-06 | 4.81e-05 | 116 |
GO:1901654112 | Skin | cSCC | response to ketone | 79/4864 | 194/18723 | 4.82e-06 | 7.06e-05 | 79 |
GO:0010950112 | Skin | cSCC | positive regulation of endopeptidase activity | 74/4864 | 179/18723 | 4.98e-06 | 7.25e-05 | 74 |
GO:003629326 | Skin | cSCC | response to decreased oxygen levels | 119/4864 | 322/18723 | 7.98e-06 | 1.09e-04 | 119 |
GO:003109924 | Skin | cSCC | regeneration | 79/4864 | 198/18723 | 1.18e-05 | 1.51e-04 | 79 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CFLAR | SNV | Missense_Mutation | | c.670N>A | p.Val224Met | p.V224M | O15519 | protein_coding | deleterious(0.04) | possibly_damaging(0.798) | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CFLAR | SNV | Missense_Mutation | novel | c.1152N>C | p.Glu384Asp | p.E384D | O15519 | protein_coding | tolerated(0.56) | benign(0.003) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CFLAR | SNV | Missense_Mutation | novel | c.565G>T | p.Ala189Ser | p.A189S | O15519 | protein_coding | tolerated(1) | benign(0) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CFLAR | insertion | In_Frame_Ins | novel | c.1150_1151insTTTTCCCCAGAGCTTCTTCGAGACACCTTC | p.Glu384delinsValPheProArgAlaSerSerArgHisLeuGln | p.E384delinsVFPRASSRHLQ | O15519 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CFLAR | insertion | Nonsense_Mutation | novel | c.700_701insCACTGTAGCCAGACTGCCTCTCTAGA | p.Phe234SerfsTer3 | p.F234Sfs*3 | O15519 | protein_coding | | | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
CFLAR | SNV | Missense_Mutation | | c.1143G>T | p.Lys381Asn | p.K381N | O15519 | protein_coding | tolerated(0.4) | benign(0.015) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CFLAR | SNV | Missense_Mutation | | c.877N>A | p.Leu293Ile | p.L293I | O15519 | protein_coding | tolerated(0.08) | possibly_damaging(0.906) | TCGA-AA-A01Z-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CFLAR | SNV | Missense_Mutation | novel | c.803N>A | p.Arg268Gln | p.R268Q | O15519 | protein_coding | tolerated(0.36) | benign(0.003) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
CFLAR | SNV | Missense_Mutation | | c.653N>A | p.Gly218Asp | p.G218D | O15519 | protein_coding | tolerated(0.56) | benign(0) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CFLAR | SNV | Missense_Mutation | novel | c.191N>A | p.Arg64Gln | p.R64Q | O15519 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | BAY-11-7085 | BAY-11-7085 | 22326395 |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | DEHYDROEQUOL | IDRONOXIL | |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | FINASTERIDE | FINASTERIDE | 11399535 |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | BICALUTAMIDE | BICALUTAMIDE | 22623731 |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | NINTEDANIB | NINTEDANIB | |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | CABOZANTINIB | CABOZANTINIB | |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | DOVITINIB | DOVITINIB | |